Berkeley Premium sold
This article was originally published in The Tan Sheet
Executive Summary
Pristine Bay LLC, an Ohio real estate development entity, purchases Cincinnati-based Berkeley Premium Nutraceuticals in a bankruptcy auction for $2.75 million, says attorney Kim Martin Lewis. A judge in the U.S. Bankruptcy Court for the Southern District of Ohio, Western Division, approved the sale Dec. 11, but it likely will not close for a few weeks, according to Lewis, a partner in the Cincinnati office of Dinsmore & Shohl. Berkeley Premium filed for Chapter 11 protection in September (1"The Tan Sheet" Sept. 22, 2008, In Brief)
You may also be interested in...
Berkeley Premium bankrupt
The much-maligned marketer of Enzyte "natural male enhancement" supplement files for Chapter 11 bankruptcy protection Sept. 16. Cincinnati-based Berkeley Premium Nutraceuticals submits its petition to the U.S. Bankruptcy Court for the Southern District of Ohio declaring about $500 million in unsecured claims owed to its 20 largest creditors, including a $459.5 million forfeiture to the federal government ordered Aug. 27. The bankruptcy petition notes that "the debtor's problems began in approximately 2004" with a Federal Trade Commission investigation into "alleged improper marketing activities," and culminated in August with the criminal sentencing of the firm's founder after convictions of money laundering, conspiracy and fraud (1"The Tan Sheet" Sept. 1, 2008, p. 3)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.